Progyny (PGNY) Q2 2026 earnings review
Profitability Surges Past Revenue Drag
Progyny navigated the final quarter of a major client departure with a strong profitability beat. While headline revenue growth looks artificially sluggish at 5.3% YoY, Net Income skyrocketed 64% to $28.1M, driven by significant gross margin expansion (+180 bps). Management continues to optimize care delivery efficiencies while repurchasing shares heavily. Despite seasonal volume dips forecasted for Q3, the underlying ex-client revenue growth of 11% confirms that the core demand engine remains intact.
🐂 Bull Case
Excluding the $17.2M headwind from a departing large client in the prior year period, core revenue grew 11%. The transition period for this client is now entirely over, setting up cleaner, Accelerating YoY comps for the second half of the year.
Gross margin expanded to 25.5% (from 23.7%), and Adjusted EBITDA grew 7.2% despite planned platform investments. The company is extracting true operating leverage from its care management infrastructure.
🐻 Bear Case
Pharmacy benefit services revenue grew a meager 1.2% YoY, vastly underperforming the medical fertility segment (+7.6%). This suggests potential pricing pressure or shifts in treatment mix.
Q3 2026 revenue guidance of $335-345M implies a sequential revenue contraction from Q2's $350.5M, which management attributes to pronounced summer seasonality.
⚖️ Verdict: 🟢
Bullish. The drag from the massive client loss is now officially in the rearview mirror. With underlying growth in the double digits, record margins, and aggressive share repurchases, the business is structurally healthier today than it was a year ago.
Key Themes
Gross Margin Expansion
A key highlight of the quarter is the Stable to Accelerating margin profile. Gross margin jumped 180 basis points to 25.5%. This improvement was driven by structural efficiencies realized in the delivery of care management services, supplemented by a YoY decrease in stock-based compensation expense (which fell to $6.1M in COGS from $9.5M).
Pharmacy Segment Deceleration
While overall demand is framed positively, the Pharmacy benefit services segment contradicts the rosy narrative. Pharmacy revenue growth Decelerated sharply to just 1.2% YoY ($120.3M vs $118.9M), while Fertility benefit services grew 7.6%. Given the historical correlation between medical cycles and Rx attachments, this massive divergence suggests either aggressive pricing concessions, lower drug utilization per cycle, or a shift in client benefit adoption.
Underlying Client Growth Ex-Headwind
The company added 62 net new clients YoY, bringing the total to 604 clients (+11.4%). Total covered lives increased by 6.6% to 7.185 million. Because Q2 2026 had $0 contribution from a large client that provided $17.2M in Q2 2025, the underlying volume machine is actively replacing lost bulk with a more diversified, higher-margin client base.
Demographic Macro Tailwinds
Despite ongoing investor anxiety regarding general labor market softness, Progyny continues to ride a specific demographic wave: delayed family building. With the average Progyny IVF patient aged 36, and national data indicating rising birth rates exclusively among women 30+, the structural demand for the company's core services remains insulated from broader macroeconomic cycles.
Sequential Demand Contraction in Q3
Management's Q3 guidance signals a Reversing trend sequentially. Revenue is guided down to $340M (midpoint) from Q2's $350.5M. The company cited a 'slightly more pronounced seasonal impact' as member engagement typically lessens during summer months. While YoY growth remains positive, this sequential dip places higher execution pressure on Q4 to hit full-year targets.
Other KPIs
Slightly Decelerating YoY from $55.5 million in 25Q2. The slight drop reflects the timing impact of working capital items. However, the company continues to successfully convert over 75% of its Adjusted EBITDA into operating cash flow, boasting a robust $201.2 million in TTM OCF.
The company repurchased nearly 1.2 million shares in Q2 under its new May 2026 program. Combined with the predecessor program, Progyny has retired an aggregate 10.8 million shares, demonstrating immense management confidence and utilizing the unlevered balance sheet (zero debt, $236.9M in cash/securities).
Guidance
Accelerating on a YoY basis. The $340M midpoint implies 8.5% YoY growth (compared to Q3 2025's $313.3M). However, this represents a sequential deceleration from Q2's $350.5M, driven by summer seasonality.
Stable. The $57.5M midpoint represents a slight expansion from Q3 2025's $55.0M, but implies a margin of roughly 16.9%, which is a sequential dip from Q2's robust 17.7%, reflecting ongoing platform investments.
Stable. This projects 5.5% to 7.5% headline growth over 2025, but a much healthier 9.7% to 11.7% growth when excluding the $48.5M transition revenue collected from a departed large client in the first half of 2025.
Accelerating. Implies massive bottom-line growth compared to historicals, driven by care management efficiencies and the expiration of legacy stock-based compensation grants. Midpoint Adjusted EPS is guided at $2.07.
Key Questions
Pharmacy Underperformance
Pharmacy revenue grew only 1.2% this quarter while Medical grew 7.6%. Are we seeing structural changes to Rx pricing or lower drug utilization per cycle?
Seasonal Severity
You cited a 'more pronounced seasonal impact' causing the expected sequential revenue drop in Q3. Is this a change in consumer behavior (delaying treatments for travel), or driven by a specific mix of clients?
Selling Season Update
Now that we are in the 'heart of the selling season,' how is the early pipeline conversion for 'not nows' (employers who deferred decisions last year) performing compared to internal expectations?